Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

    NEXT STORY
    DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies
    PREV STORY
    Policy thought-leaders, Don Drummond and Duncan Sinclair, release long-term care report seeking to reshape the future for Canadian seniors
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment With Leading U.S. Biotech Funds

    BERKELEY, Calif. and VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics ...

    author_avatar
    NASDAQ Market News

    Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)

    Three- and four-year data continued to show reduction in amyloid plaque and to suggest ...

    author_avatar
    NASDAQ Market News

    PositiveID’s ExcitePCR Named Major Player in Molecular Diagnostics Industry Report

    DELRAY BEACH, Fla., Dec. 14, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (the “Company”) (OTC:PSID), ...

    author_avatar
    NASDAQ Market News